Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not ri...
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
About this item
Full title
Author / Creator
Publisher
London: Springer London
Journal title
Language
English
Formats
Publication information
Publisher
London: Springer London
Subjects
More information
Scope and Contents
Contents
Summary
A retrospective study of 121 patients who stopped denosumab (Dmab) then received no treatment (NT), risedronate (RIS), alendronate (ALN), or zoledronic acid (ZOL). Bone density (spine and hip) during and after Dmab discontinuation was measured. Treatment with ALN or ZOL, not NT and RIS, mitigated BMD loss after Dmab discontinuation.
I...
Alternative Titles
Full title
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9813893
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9813893
Other Identifiers
ISSN
0937-941X
E-ISSN
1433-2965
DOI
10.1007/s00198-022-06648-9
